Join Matindale-Hubbell Connected



Search Results (2745)

  
Documents on biotech life sciences
 

View Page: <<  Prev  11  12  13  14  15  16  17  18  19  20  Next  >>
Show: results per page
Sort by:
Sponsored Results

HTMLKey Questions to Ask When Preparing a Data Breach Response Plan (Part II)
Peter I. Sanborn; Foley & Lardner LLP;
Legal Alert/Article
May 22, 2014, previously published on May 16, 2014
Following up on last week’s post, we return to the wide range of questions about a company’s operations that can guide a team building a data breach response plan to cover many of the risks encountered in the wake of a breach.

 

HTMLFederal Circuit Keeps Burden of Patent Clarity on Applicants on Issues of Patent Indefiniteness
Courtenay C. Brinckerhoff; Foley & Lardner LLP;
Legal Alert/Article
May 22, 2014, previously published on May 8, 2014
In In re Packard, the Federal Circuit affirmed the USPTO Patent Trial and Appeal Board (PTAB) decision upholding the rejection of Packard’s claims for indefiniteness. The per curiam decision approaches the issue from the perspective of the USPTO’s examination function, while steering...

 

HTMLStakeholders Testify on Patent Subject Matter Eligibility
Leon Y. Lum; Foley & Lardner LLP;
Legal Alert/Article
May 16, 2014, previously published on May 15, 2014
On May 9, 2014, the USPTO held a public forum on the USPTO’s new patent subject matter eligibility guidance (the “Guidance”). In promoting the forum, the USPTO stated that it wished to “to receive public feedback from organizations and individuals on the Guidance.” The...

 

HTMLBaaaaad News for Patenting Cloned Sheep
Courtenay C. Brinckerhoff; Foley & Lardner LLP;
Legal Alert/Article
May 13, 2014, previously published on May 9, 2014
In a unanimous panel decision, the Federal Circuit affirmed the finding of the USPTO Patent Trial and Appeal Board (PTAB) that claims directed to cloned cattle, sheep, pigs and goats were directed to non-patent eligible subject matter under 35 USC § 101. The court in effect held that while...

 

HTMLThe New USPTO Patent Eligibility Rejections Under Section 101
Courtenay C. Brinckerhoff; Foley & Lardner LLP;
Legal Alert/Article
May 12, 2014, previously published on May 6, 2014
Well, it’s happening. Office Actions with new patent eligibility rejections based on the USPTO’s March 4, 2014 Guidance are being mailed out to patent practitioners across the nation. While some new rejections under §101 were expected, others have been more surprising. The most...

 

HTMLFederal Circuit Affirms Validity of Tarka Patent on Combination Pharmaceutical Product
Courtenay C. Brinckerhoff; Foley & Lardner LLP;
Legal Alert/Article
May 6, 2014, previously published on May 1, 2014
The Federal Circuit decision in Sanofi-Aventis Deutschland GmbH v. Glenmark Pharmaceuticals Inc., USA, addresses several interesting issues, but is most likely to be cited by other patent holders for its affirmance of the jury verdict that upheld the Tarka patent at issue. The jury found that...

 

HTMLHigh Octane Patent Litigation? Supreme Court Relaxes Standards for Awarding Attorneys' Fees While Increasing Deference on Appeal
Sutherland Asbill Brennan LLP;
Legal Alert/Article
May 5, 2014, previously published on April 29, 2014
In twin unanimous opinions issued today, the U.S. Supreme Court has rejected long-standing Federal Circuit rules governing the award of attorneys’ fees to the prevailing party in patent litigation, and appellate review of those awards. The decisions give district judges more discretion to...

 

HTMLCDRH Announces Expedited Access PMA Program to Speed Development and Approval of Devices that Treat or Diagnose a Life-Threatening or Debilitating Disease and Meet an Unmet Medical Need
Jamie K. Wolszon; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
May 2, 2014, previously published on April 30, 2014
Earlier this month, FDA’s Center for Devices and Radiological Health (“CDRH”) announced a new voluntary “expedited access premarket approval (“PMA”) program” intended to speed development and approval of devices that treat or diagnose a life-threatening or...

 

Adobe PDFIndustrial Site Recovery Act: An Environmental Consideration For New Jersey Life Sciences Facilities
Lisa Murtha Bromberg, Thomas Spiesman; Porzio, Bromberg & Newman P.C.;
Legal Alert/Article
April 30, 2014, previously published on April 2014
Life sciences companies must consider the applicability and requirements of various environmental laws and regulations that may apply to operations and transactions.

 

HTMLPatent-Eligibility of Stem Cells Under New USPTO "Myriad-Mayo" Guidance
Antoinette F. Konski; Foley & Lardner LLP;
Legal Alert/Article
April 30, 2014, previously published on April 28, 2014
In March, the U.S. Patent and Trademark Office (USPTO) implemented new procedures to address whether inventions that relate in whole or in part to laws of nature and naturally occurring products are patent-eligibility in light of recent U.S. Supreme Court decisions, notably Association for...

 


View Page: <<  Prev  11  12  13  14  15  16  17  18  19  20  Next  >>